Dr Reddy’s to buy Novartis’s cardio drug Cidmus for Rs 463 crore - Moneycontrol

In a statement on April 1, Dr Reddy’s said the Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ej…

Indian generic drug maker Dr Reddys Laboratories has agreed to acquire the cardiovascular brand Cidmus from global pharmaceutical giant Novartis AG for $61 million (approximately Rs 463 crore). This… [+1665 chars]

full article...